SMi Group's 14th annual Pain Therapeutics conference

529 views

Published on

SMi Group's Pain Therapeutics returns for its 14th year next may in London

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
529
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

SMi Group's 14th annual Pain Therapeutics conference

  1. 1. REGISTER BY 28TH FEBRUARY AND RECEIVE A £300 DISCOUNT REGISTER BY 31ST MARCH AND RECEIVE A £100 DISCOUNT SMi present the 14th Annual Conference on… PAIN THERAPEUTICS Assess Alternative Approaches to Animal Models to Minimise the Translational Gap and Accelerate Market Access 19TH - 20TH MAY 2014 Holiday Inn Regents Park Hotel, London, UK CONFERENCE CHAIRS FOR 2014: • Jordi Serra, Chief Scientific Officer, Neuroscience Technologies Ltd • Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research & Development L.L.C. KEY SPEAKERS INCLUDE: • Samer Eid, Director, Neuroscience Scientific Knowledge Discovery, Merck • Tom McCarthy, CEO, Spinifex • Zara Sands, Principal Scientist, Computational Medicinal Chemist, UCB • Birgit Priest, Research Advisor, Eli Lilly • Philip R Kym, Director of Chemistry, Centralised Lead, Optimisation, AbbVie • Stephen Wright, R&D Director, GW Pharmaceuticals BUSINESS BENEFITS FOR 2014: • Discuss and evaluate the latest new therapeutic mechanisms from bench to bedside with key insight from Merck, Spinifiex, Eli Lilly, AbbVie and UCB • Hear key presentations from Mundipharma Research and Nektar on advances to opioids and strategies to reduce abuse potential • Explore the latest in the area of Neuropathic pain for 2014 with the latest case studies from Neuroscience Technologies and GW Pharmaceuticals • Evaluate the translation gap with case studies from a pre-clinical and clinical perspective from Karolinska Institutet and OGBConsulting PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS Wednesday 21st May 2014, Holiday Inn Regents Park Hotel, London, UK A: How Can Success in Analgesia be Improved? B: Opportunities for Collaborative Pain Projects Workshop Leaders: Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals Birgit Priest, Research Advisor, Eli Lilly 8.30am - 12.30pm Workshop Leader: Fiona Boissonade, Head of Neuroscience, University of Sheffield 1.30pm - 5.30pm www.pain-therapeutics.co.uk BOOK BY 28TH FEBRUARY AND SAVE £300 / BOOK BY 31ST MARCH AND SAVE £100 Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
  2. 2. Pain Therapeutics www.pain-ther Day One | Monday 19th May 2014 8.30 Registration & Coffee 12.50 Networking Lunch 9.00 Chairman's Opening Remarks Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research & Development L.L.C. 1.50 How do we produce a step change in the discovery of new analgesics? • Epigenetic proteins are fundamental mediators of chronic pain pathology • In early discovery, more open partnerships between academia and industry are critical • In vitro clinical assays are likely more predictive of activity in patients Chas Bountra, Chief Scientist (SGC), Professor of Translational Medicine, University of Oxford 2.30 Highlights from AbbVie pain research: TRPV1, TrkA, Cav2.2, and Nav1.7 • The discovery of modality specific TRPV1 antagonists that demonstrate reduced liabilities with respect to core body temperature increase and the loss of sensation of noxious heat • The discovery of Cav2.2 and Nav1.7 clinical candidates for the treatment of chronic pain • The discovery of TrkA inhibitors for the treatment of chronic pain Philip R Kym, Director of Chemistry, Centralised Lead Optimisation, AbbVie 3.10 Afternoon Tea ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE PART ONE 9.10 9.50 10.30 11.00 OPENING ADDRESS Accelerating innovation in research to build the pain pipeline • Filling the pain clinical development pipeline • Open innovation in pain research • Novel targets/mechanisms and new directions in pain research Samer Eid, Director, Neuroscience Scientific Knowledge Discovery, Merck How can in silico approaches be used to prospectively drive membrane protein drug discovery programs? • Importance of establishing expectations and aligning resources accordingly • Examples of effective applications of computational approaches for driving drug design cycles • Potential pit falls and future prospects Zara Sands, Principal Scientist, Computational Medicinal Chemist, UCB Morning Coffee ENHANCING THE TRANSLATION OF ANIMAL DATA INTO PAIN PATIENTS KEYNOTE PRESENTATION Mechanistic studies supporting the angiotensin II type 2 receptor antagonist MOA in chronic pain through to presentation of Phase 2 efficacy and safety data • Efficacy and safety data from Phase 2 clinical trial of EMA401 in postherpetic neuralgia. • Mechanism of action studies in human sensory neurons and clinical tissues. • Update on ongoing clinical trials of EMA401. Tom McCarthy, CEO, Spinifex Praveen Anand, Professor of Clinical Neurology, Lead Clinician for Pain Services, Imperial College Healthcare NHS Trust 3.40 The translational gap and assessing failures case study 1: pre-clinical perspective • Experimental models versus clinical trials • Translation from animal models to man • Failed pain mechanisms? Professor Odd-Geir Berge, Independent Consultant, OGBConsulting 4.20 The translational gap and assessing failures case study 2: clinical perspective • Translation from a clinical perspective • Human proof of concept • Failed mechanisms or failed studies? Jarkko Kalliomaki, MD, PhD, Clinical Pain Research, Dept of Molecular Medicine and Surgery, Karolinska Institutet 5.00 Chairman's Closing Remarks and Close of Day One Q&A Session 12.20 Round Table Discussion: Should animal models only be used for PK/PD testing for exposure of the compound? ROUND TABLE DISCUSSION Register online at: www.pain-therapeutics.co.uk • Alternatively fax Who should attend: Heads of Department, Directors, Managers, Team Leaders Researchers and Scientists from: • Clinical Trials • Neuroscience • Translational Medicine/R&D • Pain and inflammation target discovery • Analgesic preclinical development • CNS clinical trials • Translational imaging • Early phase CNS research • Epigenetics in pain and inflammation • Chronic and neuropathic pain • Clinical trial design • Pain Management SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk Want to know how you can get involved? Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162, or email: tarri@smionline.co.uk
  3. 3. apeutics.co.uk 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Jordi Serra, Chief Scientific Officer, Neuroscience Technologies Ltd Day Two | Tuesday 20th May 2014 ASSESSING NEW MECHANISMS - BENCH TO BEDSIDE PART 1.20 New Tools in the Translation from Bench to Clinic TWO • Failure of recent developmental compounds to demonstrate analgesic efficacy in the clinic • Possible explanations based on divergent pharmacology • New tools and approaches to better predict human pharmacology and efficacy Birgit Priest, Research Advisor, Eli Lilly 2.00 Overview of Fulranumab Clinical Development • Nerve Growth factor (NGF) is elevated in tissues in response to injury and inflammation • Antibody inhibitors of NGF have shown efficacy in treating pain • Fulranumab is a fully human monoclonal antibody inhibitor of NGF in development • Phase 2 efficacy and safety data for fulranumab will be presented Dr Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research & Development L.L.C. 2.40 Afternoon Tea ADVANCES IN OPIOIDS 9.10 9.50 Opioids and the treatment of Chronic Pain • The old and the new formulation of OxyContin – what is it all about or what is the difference? • Reviewing novel formulation strategies to reduce opioid abuse • Analysing the recent advances to opioids – moving forward Alexander Oksche, Executive Director of Pharmacological Intelligence, Mundipharma Research SPOTLIGHT PRESENTATION Novel Opioid Therapeutics with Intrinsically Reduced Abuse Potential • NKTR-181, a slow brain entry opioid for Chronic Pain • Opioid therapeutics with novel pharmacology for the treatment of acute pain Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals 10.30 Morning Coffee 11.00 Zero Tolerance for Chronic Pain Growth factor signaling selectively mediates tolerance to morphine • Growth factor inhibition eliminates or reverses morphine tolerance. • Newly discovered relationships between opioid tolerance and neuropathic pain suggests that this class of drugs could become important therapeutic targets for pain treatment. Howard B. Gutstein, MD, Professor, Departments of Anesthesiology and Biochemistry/Molecular Biology MD Anderson Cancer Center, Founder, Morpheus Pharmaceuticals 11.40 12.20 NEUROPATHIC PAIN 3.10 Microneurography as a method for recording individual action potentials from nociceptors and its value in drug development in neuropathic pain. • Analysing analgesic efficacy in preclinical animal models • Reviewing proof-of-concept studies that allow critical testing of presumed mechanism of action • Recording individual action potentials from single sensory fibres, including nociceptors to detect and quantify abnormal activity in human pain fibres Jordi Serra, Chief Scientific Officer, Neuroscience Technologies Ltd 3.50 Cannabinoids in neuropathic pain: What have we learnt? • Responses to cannabinoids across different neuropathic pain types • The importance of non-psychoactive cannabinoids • Cannabinoid modulation of neurotransmission vs inflammation Stephen Wright, R&D Director, GW Pharmaceuticals Discussion Panel: Strategies for reduced PANEL abuse potential DEBATE • Insights into the future of opioids • Assessing alternatives to opioid therapeutics • Evaluating how to move forward to minimise opioid misuse Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals Alexander Oskche, Executive Director of Pharmacological Intelligence, Mundipharma Research Howard B. Gutstein, MD, Professor, Departments of Anesthesiology and Biochemistry/Molecular Biology MD Anderson Cancer Center, Founder, Morpheus Pharmaceuticals 4.30 Advances into new therapeutic strategies for pain reduction • Assessing the correlation between molecular targets and the degree of pain • Reviewing molecule-to-man studies combining molecular genetics, molecular biology, and biophysics • Demonstrating the contribution of ion channels to human pain and the importance for axonal conduction Fiona Boissonade, Head of Neuroscience, University of Sheffield Networking Lunch 5.10 Chairman’s Closing Remarks and Close of Day Two x your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Official Media Partners Supported by
  4. 4. INTERACTIVE POST-CONFERENCE WORKSHOP Wednesday 21st May 2014 Holiday Inn Regents Park Hotel, London, UK 8.30am - 12.30pm A: How Can Success in Analgesia be Improved? Workshop Leaders: Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals Birgit Priest, Research Advisor, Eli Lilly Overview of the workshop Lack of efficacy is the root cause for approximately half of failures both in Phase II and Phase III. This workshop will focus on addressing the issues that are arising and evaluating how to improve clinical trial design to ensure success. Steve will address Nektar’s approach to improving success, improving the efficacy and safety of drugs known to work in the clinic. What approaches have the Industry taken to address this? • Linkage between target and disease • Disconnect between animal and human data (what models are truly translational?) • Phenotypic vs. target-based screening Key Benefits of Attending: • Gain understanding on ways to address issues arising in clinical trial design • Learn how to identifying key challenges in design when benchmarking • Enhance the translational gap between animal and human models • Review phenotypic vs. target-based screening Programme 8.30 Registration and Coffee 9.00 Introduction on identifying key challenges in clinical trial design with a real life scenario given as the simulation exercise 10.30 Coffee Break 11.00 The group will discuss ways to address key issues arising in clinical trial design 11.30 Assessing the translational gap between animal and human models 12.30 Close of Workshop About the workshop host Steve Harrison is responsible for the research biology activities at Nektar Therapeutics and leads efforts that identify potential new drugs to treat pain and cancer. His team supports the transition of these new agents into clinical testing. Prior to joining Nektar, Steve was Senior Vice President of Research at KAI Pharmaceuticals and led the Discovery and Preclinical efforts for that company, involving support for clinical development of agents in pain, cardiovascular disease and renal dysfunction. Birgit Priest received her Ph. D. in Biochemistry & Biophysics from Oregon State University in 1993. Her thesis work on muscarinic receptors was completed under the guidance of Dr. Michael Schimerlik. She then trained in electrophysiology as a post-doctoral fellow in the laboratories of Dr Joseph Patlak (University of Vermont) and Dr John Adelman (Vollum Institute). In 1998, Birgit joined Merck Research Labs, where, for 13 years, she worked on a number of voltage- and ligandgated ion channel programs. At the beginning of 2011, Birgit started a position with Eli Lilly where she continues her work of ion channel drug discovery. Her primary research interest has been in the role of sodium channels in sensory functions.
  5. 5. INTERACTIVE POST-CONFERENCE WORKSHOP Wednesday 21st May 2014 Holiday Inn Regents Park Hotel, London, UK 1.30pm - 5.30pm B: Opportunities for Collaborative Pain Projects Workshop Leader: Fiona Boissonade, Head of Neuroscience, University of Sheffield Overview of the workshop In modern drug discovery the path from concept to patient is more and more dependent on collaborations (as opposed to the “old world” where everything was done within big pharma companies). Centres of excellence are formed in large pharma companies that coordinate work performed at contract research organisations (CROs), academia and public institutions. Also, centres dedicated to drug discovery outside of the traditional private sector are starting to emerge. Among the challenges: how to achieve transparency between the partners (e.g. academia and industry). This workshop will enable Industry and Academia to discuss the alliances which hold great benefit specifically related to pain projects for novel analgesics. Short Case studies from Pharma and Academia will kick-off the discussion which will lead to a stronger working approach for targeting novel pain therapeutics. Key Benefits of Attending • Gain insight on how existing alliances are making progress • Discuss the enhancements to ensure collaborations are successful • Hear the latest case studies with strategies on how to address benefits when making a cooperation between Pharmaceutical Companies and Academic Institutions • Learn what companies and academics look to achieve from these partnerships Programme 1.30 Registration and Coffee 2.00 Reviewing existing alliances and making progress to partnerships 2.30 Discussing how to enhance collaborations to ensure they’re successful 3.00 Afternoon Tea 3.30 Evaluating strategies on how to address benefits when make a cooperation between Pharmaceutical Companies and Academic institutions 4.30 Learn what companies and academics look to achieve from partnerships 5.30 Close of Workshop About the workshop host Fiona Boissonade is a dental surgeon and Professor of Neuroscience at the University of Sheffield School of Clinical Dentistry, where she leads the Neuroscience Research Group. Her major research interest is in the mechanisms of altered neuronal excitability that occur under the pathological conditions of nerve injury and inflammation, and which contribute to the development of chronic pain. Her work focuses on interdisciplinary studies funded by RCUK, industry and research charities. A significant portion of this research has been done at the academic–industrial interface; collaborations with GlaxoSmithKline, Pfizer, Eli Lilly and Renovo have funded a wide range of pre-clinical translational studies related to pain and nerve regeneration. She also has a number of collaborations with other academic researchers at the University of Sheffield and other universities in the UK and overseas (eg Leeds University, Karolinska Institute, Yale University).
  6. 6. PAIN THERAPEUTICS Conference: Monday 19th and Tuesday 20th May 2014, Holiday Inn Regents Park Hotel, London, UK Workshop: Wednesday 21st May 2014, London 4 WAYS TO REGISTER www.pain-therapeutics.co.uk FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ DISCOUNT □ Book by 28th February to receive £300 off the conference price Book by 31st March to receive £100 off the conference price CONFERENCE PRICES Unique Reference Number Our Reference LV P-104 DELEGATE DETAILS Please complete fully and clearly in capital letters. Please photocopy for additional delegates. Title: Forename: Surname: Job Title: I would like to attend: (Please tick as appropriate) COMMERCIAL ORGANISATIONS □ Conference and 2 Workshops □ Conference and 1 workshop □ Conference only □ 2 Workshops only □ 1 workshop only □ Workshop A □ Workshop B Fee £2697.00 £2098.00 £1499.00 £1198.00 £599.00 Total +VAT +VAT +VAT +VAT +VAT £3236.40 £2517.60 £1798.80 £1437.60 £718.80 + VAT £1198.80 PROMOTIONAL LITERATURE DISTRIBUTION Department/Division: □ Distribution of your company’s promotional literature to all conference attendees £999.00 Company/Organisation: Email: Company VAT Number: The conference fee includes refreshments, lunch, conference papers and access Address: to the Document Portal containing all of the presentations. LIVE STREAMING/ON DEMAND/ DOCUMENTATION Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room. Price Total □ Live Streaming □ On demand Mobile: Switchboard: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. ACCOUNTS DEPT Title: £999.00 + VAT (UK) £1198.80 £599.00 + VAT (UK) £718.80 (available 24 hours after the event) □ Access to the conference documentation on the Document Portal £499.00 + VAT £499.00 (or only £300 if ordered with the Document Portal) □ The Conference Presentations - paper copy Forename: £598.80 £499.00 Surname: Email: PAYMENT Address (if different from above): Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-104 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE Holiday Inn, Regents Park, Carburton Street, London, W1W 5EE □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. □ UK BACS □ Wire Transfer □ Cheque □ Credit Card Sort Code 300009, Account 00936418 Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 We can only accept Sterling cheques drawn on a UK bank. □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Card No: Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk

×